Cell-mediated drug delivery

Elena V. Batrakova, Howard Eliot Gendelman, Alexander V. Kabanov

Research output: Contribution to journalReview article

147 Citations (Scopus)

Abstract

Introduction: Drug targeting to sites of tissue injury, tumor or infection with limited toxicity is the goal for successful pharmaceutics. Immunocytes (including mononuclear phagocytes (dendritic cells, monocytes and macrophages), neutrophils and lymphocytes) are highly mobile; they can migrate across impermeable barriers and release their drug cargo at sites of infection or tissue injury. Thus, immune cells can be exploited as Trojan horses for drug delivery. Areas covered: This paper reviews how immunocytes laden with drugs can cross the blood-brain or blood-tumor barriers to facilitate treatments for infectious diseases, injury, cancer, or inflammatory diseases. The promises and perils of cell-mediated drug delivery are reviewed, with examples of how immunocytes can be harnessed to improve therapeutic end points. Expert opinion: Using cells as delivery vehicles enables targeted drug transport and prolonged circulation times, along with reductions in cell and tissue toxicities. Such systems for drug carriage and targeted release represent a new disease-combating strategy being applied to a spectrum of human disorders. The design of nanocarriers for cell-mediated drug delivery may differ from those used for conventional drug delivery systems; nevertheless, engaging different defense mechanisms in drug delivery may open new perspectives for the active delivery of drugs.

Original languageEnglish (US)
Pages (from-to)415-433
Number of pages19
JournalExpert Opinion on Drug Delivery
Volume8
Issue number4
DOIs
StatePublished - Apr 1 2011

Fingerprint

Pharmaceutical Preparations
Drug Delivery Systems
Wounds and Injuries
Neoplasms
Expert Testimony
Phagocytes
Infection
Dendritic Cells
Communicable Diseases
Monocytes
Neutrophils
Macrophages
Lymphocytes
Brain
Therapeutics

Keywords

  • Cell carriers
  • drug delivery
  • immunocytes
  • nanoparticles
  • targeted drug transport

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Cell-mediated drug delivery. / Batrakova, Elena V.; Gendelman, Howard Eliot; Kabanov, Alexander V.

In: Expert Opinion on Drug Delivery, Vol. 8, No. 4, 01.04.2011, p. 415-433.

Research output: Contribution to journalReview article

Batrakova, Elena V. ; Gendelman, Howard Eliot ; Kabanov, Alexander V. / Cell-mediated drug delivery. In: Expert Opinion on Drug Delivery. 2011 ; Vol. 8, No. 4. pp. 415-433.
@article{75294b37a7c143cfab3f65015de10fc7,
title = "Cell-mediated drug delivery",
abstract = "Introduction: Drug targeting to sites of tissue injury, tumor or infection with limited toxicity is the goal for successful pharmaceutics. Immunocytes (including mononuclear phagocytes (dendritic cells, monocytes and macrophages), neutrophils and lymphocytes) are highly mobile; they can migrate across impermeable barriers and release their drug cargo at sites of infection or tissue injury. Thus, immune cells can be exploited as Trojan horses for drug delivery. Areas covered: This paper reviews how immunocytes laden with drugs can cross the blood-brain or blood-tumor barriers to facilitate treatments for infectious diseases, injury, cancer, or inflammatory diseases. The promises and perils of cell-mediated drug delivery are reviewed, with examples of how immunocytes can be harnessed to improve therapeutic end points. Expert opinion: Using cells as delivery vehicles enables targeted drug transport and prolonged circulation times, along with reductions in cell and tissue toxicities. Such systems for drug carriage and targeted release represent a new disease-combating strategy being applied to a spectrum of human disorders. The design of nanocarriers for cell-mediated drug delivery may differ from those used for conventional drug delivery systems; nevertheless, engaging different defense mechanisms in drug delivery may open new perspectives for the active delivery of drugs.",
keywords = "Cell carriers, drug delivery, immunocytes, nanoparticles, targeted drug transport",
author = "Batrakova, {Elena V.} and Gendelman, {Howard Eliot} and Kabanov, {Alexander V.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1517/17425247.2011.559457",
language = "English (US)",
volume = "8",
pages = "415--433",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Cell-mediated drug delivery

AU - Batrakova, Elena V.

AU - Gendelman, Howard Eliot

AU - Kabanov, Alexander V.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Introduction: Drug targeting to sites of tissue injury, tumor or infection with limited toxicity is the goal for successful pharmaceutics. Immunocytes (including mononuclear phagocytes (dendritic cells, monocytes and macrophages), neutrophils and lymphocytes) are highly mobile; they can migrate across impermeable barriers and release their drug cargo at sites of infection or tissue injury. Thus, immune cells can be exploited as Trojan horses for drug delivery. Areas covered: This paper reviews how immunocytes laden with drugs can cross the blood-brain or blood-tumor barriers to facilitate treatments for infectious diseases, injury, cancer, or inflammatory diseases. The promises and perils of cell-mediated drug delivery are reviewed, with examples of how immunocytes can be harnessed to improve therapeutic end points. Expert opinion: Using cells as delivery vehicles enables targeted drug transport and prolonged circulation times, along with reductions in cell and tissue toxicities. Such systems for drug carriage and targeted release represent a new disease-combating strategy being applied to a spectrum of human disorders. The design of nanocarriers for cell-mediated drug delivery may differ from those used for conventional drug delivery systems; nevertheless, engaging different defense mechanisms in drug delivery may open new perspectives for the active delivery of drugs.

AB - Introduction: Drug targeting to sites of tissue injury, tumor or infection with limited toxicity is the goal for successful pharmaceutics. Immunocytes (including mononuclear phagocytes (dendritic cells, monocytes and macrophages), neutrophils and lymphocytes) are highly mobile; they can migrate across impermeable barriers and release their drug cargo at sites of infection or tissue injury. Thus, immune cells can be exploited as Trojan horses for drug delivery. Areas covered: This paper reviews how immunocytes laden with drugs can cross the blood-brain or blood-tumor barriers to facilitate treatments for infectious diseases, injury, cancer, or inflammatory diseases. The promises and perils of cell-mediated drug delivery are reviewed, with examples of how immunocytes can be harnessed to improve therapeutic end points. Expert opinion: Using cells as delivery vehicles enables targeted drug transport and prolonged circulation times, along with reductions in cell and tissue toxicities. Such systems for drug carriage and targeted release represent a new disease-combating strategy being applied to a spectrum of human disorders. The design of nanocarriers for cell-mediated drug delivery may differ from those used for conventional drug delivery systems; nevertheless, engaging different defense mechanisms in drug delivery may open new perspectives for the active delivery of drugs.

KW - Cell carriers

KW - drug delivery

KW - immunocytes

KW - nanoparticles

KW - targeted drug transport

UR - http://www.scopus.com/inward/record.url?scp=79952916450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952916450&partnerID=8YFLogxK

U2 - 10.1517/17425247.2011.559457

DO - 10.1517/17425247.2011.559457

M3 - Review article

VL - 8

SP - 415

EP - 433

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 4

ER -